DexCom, Inc. (VIE:DXCM)

Market Cap	20.74B -21.3%
Revenue (ttm)	3.97B +15.6%
Net Income	712.28M +45.1%
EPS	1.78 +46.7%
Shares Out	n/a
PE Ratio	29.12
Forward PE	24.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3
Open	53.26
Previous Close	54.29
Day's Range	53.18 - 53.89
52-Week Range	47.32 - 78.28
Beta	n/a
RSI	32.24
Earnings Date	Apr 30, 2026

About DexCom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin;...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 1999
• Employees: 11,050
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: DXCM

Financial Performance

In 2025, DexCom's revenue was $4.66 billion, an increase of 15.60% compared to the previous year's $4.03 billion. Earnings were $836.30 million, an increase of 45.14%.

Financial numbers in USD